Study protocol-Evoked craving in high-dose benzodiazepine users.
abuse
addiction
benzodiazepine
cue reactivity
virtual reality
Journal
Frontiers in psychiatry
ISSN: 1664-0640
Titre abrégé: Front Psychiatry
Pays: Switzerland
ID NLM: 101545006
Informations de publication
Date de publication:
2022
2022
Historique:
received:
30
05
2022
accepted:
12
09
2022
entrez:
31
10
2022
pubmed:
1
11
2022
medline:
1
11
2022
Statut:
epublish
Résumé
Benzodiazepine (BDZ) abuse, especially concerning high doses of BDZs, is an impairing substance use disorder (SUD) that is often difficult to treat. Craving and cue reactivity (CR) are two important phenomena that have a prominent role in maintaining addiction and triggering relapses in BDZ abuse; nevertheless, they have rarely been addressed in scientific literature. The present study aims to fill these gaps by implementing a highly innovative virtual reality (VR) design to assess the impact of substance-related environmental cues on BDZ craving, as well as their influence on patients' affective states. Therefore, on one hand, this research will contribute to the assessment of VR feasibility in the study of these phenomena, and, on the other, it will help disentangle the role that CR and craving have on mood and attention, which are equally important factors to consider when treating SUDs. We will recruit a healthy control group and a patient group comprising people seeking treatment for BDZ detoxification. The experimental design will consist of the presentation of three VR scenarios, one neutral, one BDZ-related but without BDZ cues, and another with BDZ cues. The craving will be measured through a virtual analog scale (VAS); the Profile of Mood States (POMS) and Alcohol Attention Scale (AAS) questionnaires in a modified version will also be administered. We will additionally control for VR-induced feelings of sickness by administering the Simulator Sickness Questionnaire (SSQ), and the Presence Questionnaire (PQ) will be used to investigate participants' sense of presence in virtual environments. We expect patients to exhibit higher levels of craving, and that the craving will be higher after exposure to a cue-related virtual environment as compared to a neutral scenario.
Identifiants
pubmed: 36311534
doi: 10.3389/fpsyt.2022.956892
pmc: PMC9608779
doi:
Types de publication
Journal Article
Langues
eng
Pagination
956892Informations de copyright
Copyright © 2022 Zamboni, Toldo, Fusina, Mattiello, Mannari, Campagnari, Schiavone, Congiu, Verlato, Chiamulera and Lugoboni.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Br J Clin Pharmacol. 2014 Feb;77(2):295-301
pubmed: 22882333
Exp Clin Psychopharmacol. 2001 Nov;9(4):399-408
pubmed: 11764016
Addict Behav. 2018 Jun;81:1-11
pubmed: 29421343
Nicotine Tob Res. 2021 Jan 22;23(2):249-258
pubmed: 32772094
Cogn Process. 2019 Aug;20(3):291-298
pubmed: 30569268
Addict Behav. 2006 Oct;31(10):1881-94
pubmed: 16516397
Nat Rev Neurosci. 2011 Nov 03;12(12):752-62
pubmed: 22048061
Addict Behav. 2008 Jun;33(6):743-56
pubmed: 18282663
Crit Care Med. 2018 Oct;46(10):1673-1680
pubmed: 29985215
Int Clin Psychopharmacol. 2007 Sep;22(5):292-8
pubmed: 17690598
Lancet. 2019 Aug 31;394(10200):781-792
pubmed: 31478502
Front Neurosci. 2020 Jan 10;13:1409
pubmed: 31998066
Dtsch Arztebl Int. 2015 Jan 5;112(1-2):1-7
pubmed: 25613443
CNS Drugs. 2004;18(1):37-48
pubmed: 14731058
J Psychopharmacol. 2013 Nov;27(11):967-71
pubmed: 24067791
Cyberpsychol Behav Soc Netw. 2010 Apr;13(2):159-62
pubmed: 20528271
Eur J Clin Pharmacol. 2014 Mar;70(3):319-29
pubmed: 24337417
J Consult Clin Psychol. 1996 Oct;64(5):993-1002
pubmed: 8916628
Pharmacol Biochem Behav. 2010 Oct;96(4):454-60
pubmed: 20643158
Psychother Psychosom. 2015;84(5):273-83
pubmed: 26278327
Nicotine Tob Res. 2006 Oct;8(5):661-9
pubmed: 17008193
Front Psychol. 2019 Feb 04;10:158
pubmed: 30778320
Front Hum Neurosci. 2014 Oct 17;8:844
pubmed: 25368571
Int J Environ Res Public Health. 2017 Jan 04;14(1):
pubmed: 28054975
Front Psychiatry. 2022 Apr 01;13:854088
pubmed: 35432033
Alcohol Alcohol. 2018 May 01;53(3):235-240
pubmed: 29145640
Can J Aging. 2015 Jun;34(2):207-14
pubmed: 25790264
Eur Arch Psychiatry Clin Neurosci. 2018 Feb;268(1):17-26
pubmed: 28349247
Addiction. 2001 Jan;96(1):33-46
pubmed: 11177518
Drug Alcohol Depend. 2014 Sep 1;142:105-9
pubmed: 25001277
BMC Fam Pract. 2013 Dec 13;14:191
pubmed: 24330388
Curr Opin Psychiatry. 2005 May;18(3):249-55
pubmed: 16639148
Eur J Clin Pharmacol. 2011 Oct;67(10):1045-52
pubmed: 21494764
Eur Addict Res. 2021;27(6):439-446
pubmed: 33940577
Nicotine Tob Res. 2016 May;18(5):538-46
pubmed: 26453669
J Am Geriatr Soc. 2011 Oct;59(10):1883-90
pubmed: 22091502
Front Hum Neurosci. 2020 Mar 31;14:124
pubmed: 32296322
Psychol Med. 2011 Mar;41(3):629-40
pubmed: 20459881
N Engl J Med. 2017 Mar 23;376(12):1147-1157
pubmed: 28328330
Addict Behav. 2011 Nov;36(11):1068-75
pubmed: 21783326
Am J Health Syst Pharm. 2018 Jan 1;75(1):e6-e12
pubmed: 29273607
Eur J Clin Pharmacol. 2019 Aug;75(8):1117-1124
pubmed: 30915520
J Psychopharmacol. 2017 Oct;31(10):1369-1373
pubmed: 28613124
J Anxiety Disord. 2011 May;25(4):554-62
pubmed: 21315551
Alcohol Alcohol. 2019 Mar 1;54(2):167-172
pubmed: 30796778
Addict Behav Rep. 2022 Jun 26;16:100443
pubmed: 35855973
Behav Res Methods. 2007 May;39(2):175-91
pubmed: 17695343
J Clin Psychiatry. 2002 Sep;63(9):817-25
pubmed: 12363124
Brain Res Brain Res Rev. 2005 Feb;48(1):74-97
pubmed: 15708629
Drug Alcohol Depend. 2012 Sep 1;125(1-2):8-18
pubmed: 22857878
Front Psychol. 2017 Feb 13;8:185
pubmed: 28243216
Addiction. 2011 Dec;106(12):2086-109
pubmed: 21714826
J Stud Alcohol. 1993 Mar;54(2):235-45
pubmed: 8384678
Pharmacopsychiatry. 2017 Sep;50(5):189-196
pubmed: 28675912
Biol Psychiatry Cogn Neurosci Neuroimaging. 2018 Dec;3(12):1022-1031
pubmed: 30143454
J Health Care Inter Des. 1991;3:97-109
pubmed: 10123973
J Psychopharmacol. 2016 Oct;30(10):1047-53
pubmed: 27166362